Publication: Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability
Issued Date
2013-01-01
Resource Type
ISSN
10292403
10428194
10428194
Other identifier(s)
2-s2.0-84870893023
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Leukemia and Lymphoma. Vol.54, No.1 (2013), 83-89
Suggested Citation
Tanin Intragumtornchai, Udomsak Bunworasate, Noppadol Siritanaratkul, Archrob Khuhapinant, Weerasak Nawarawong, Lalita Norasetthada, Arnuparp Lekhakula, Pairaya Rujirojindakul, Chittima Sirijerachai, Kanjana Chansung, Tawatchai Suwanban, Suporn Chuncharunee, Pimjai Niparuck, Somchai Wongkhantee, Wichean Mongkonsritragoon, Tontanai Numbenjapon Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability. Leukemia and Lymphoma. Vol.54, No.1 (2013), 83-89. doi:10.3109/10428194.2012.698739 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/31427
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability
Author(s)
Tanin Intragumtornchai
Udomsak Bunworasate
Noppadol Siritanaratkul
Archrob Khuhapinant
Weerasak Nawarawong
Lalita Norasetthada
Arnuparp Lekhakula
Pairaya Rujirojindakul
Chittima Sirijerachai
Kanjana Chansung
Tawatchai Suwanban
Suporn Chuncharunee
Pimjai Niparuck
Somchai Wongkhantee
Wichean Mongkonsritragoon
Tontanai Numbenjapon
Udomsak Bunworasate
Noppadol Siritanaratkul
Archrob Khuhapinant
Weerasak Nawarawong
Lalita Norasetthada
Arnuparp Lekhakula
Pairaya Rujirojindakul
Chittima Sirijerachai
Kanjana Chansung
Tawatchai Suwanban
Suporn Chuncharunee
Pimjai Niparuck
Somchai Wongkhantee
Wichean Mongkonsritragoon
Tontanai Numbenjapon
Abstract
The impact of health insurance with inequitable rituximab coverage on the survival of patients with diffuse large B-cell lymphoma (DLBCL) has never been reported. We conducted a nationwide multicenter analysis on the outcome of 553 adult patients consecutively diagnosed with DLBCL between July 2003 and June 2006, in whom treatment cost was reimbursed under the Civil Servant Medical Benefit Scheme (CSMBS) (n =201) or the Universal Coverage Scheme (UCS) (n =352). The international prognostic index was comparable between the two payment groups. Rituximab-based therapy was administered in 45.3% and 3.1% of CSMBS and UCS patients, respectively (p <0.001). With a median follow-up of 24.6 months, the 6-year progression-free survival (PFS) was superior for CSMBS patients (34.2 vs. 23.2%, p =0.005). "Not treated with rituximab-based therapy" was the strongest adverse prognostic feature indicating a short PFS (hazard ratio 2.1, p <0.001). It is concluded that lack of access to rituximab is the principal factor accounting for the inferior PFS observed in Thai patients with DLBCL who are treated under the UCS. © 2013 Informa UK, Ltd.